Phase I-II Study of Irinotecan and Erlotinib in Patients with Erlotinib Failure for Non-Small Cell Lung Cancer
Not Applicable
- Conditions
- Erlotinib Failure for Non-Small Cell Lung Cancer
- Registration Number
- JPRN-UMIN000003102
- Lead Sponsor
- Department of Thoracic Medical Oncoligy CancernInstitute Hospital Japanese foundation for cancer reseach
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 43
Inclusion Criteria
Not provided
Exclusion Criteria
Clinically significant serious disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method